Skip to main content
Top
Published in: Indian Journal of Gastroenterology 5/2011

01-09-2011 | Short Report

Contribution of immunofluorescence to identification and characterization of antineutrophil cytoplasmic antibodies in inflammatory bowel disease

Authors: Dorra Bouzid, Samy Haddouk, Ali Amouri, Youssef Ben Hadj Hmida, Nabil Tahri, Hatem Masmoudi

Published in: Indian Journal of Gastroenterology | Issue 5/2011

Login to get access

Abstract

We evaluated the combined use of different fixatives for the identification of atypical perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) in patients with inflammatory bowel diseases (IBD) by indirect immunofluorescence (IIF). Sera from 59 ulcerative colitis (UC) and 37 Crohn’s disease (CD) patients, and from 64 healthy controls were studied. The IIF on ethanol-, formalin-, and methanol-fixed neutrophils was used for the detection of ANCA. Enzyme linked immunosorbant assay (ELISA) was performed to identify the antigens recognized by ANCA. ANCAs were present in 35 of 59 (59.3%) UC patients and in 10 of 37 (27.02%) CD patients. Atypical p-ANCA positivity was strongly associated with UC disease (44.1% in UC vs. 8.1% in CD; p = 0.0002). The combined application of different fixatives contributed to make easy the differentiation between typical p-ANCA and atypical p-ANCA. Atypical p-ANCA determination appears to be a useful parameter for the distinction between UC and CD.
Literature
1.
go back to reference Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182-205.PubMedCrossRef Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182-205.PubMedCrossRef
2.
go back to reference Desplat-Jégo S, Johanet C, Escande A, et al. Update on anti-Saccharomyces cerevisiae, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: Results of a multicenter study. World J Gastroenterol. 2007;13:2312–8.PubMed Desplat-Jégo S, Johanet C, Escande A, et al. Update on anti-Saccharomyces cerevisiae, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: Results of a multicenter study. World J Gastroenterol. 2007;13:2312–8.PubMed
3.
go back to reference Anand V, Russell AS, Tsuyuki R, Fedorak R. Perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies as serological markers are not specific in the identification of Crohn’s disease and ulcerative colitis. Can J Gasteroenterol. 2008;22:33–6. Anand V, Russell AS, Tsuyuki R, Fedorak R. Perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies as serological markers are not specific in the identification of Crohn’s disease and ulcerative colitis. Can J Gasteroenterol. 2008;22:33–6.
4.
go back to reference Savige J, Gillis D, Benson E, et al. International consensus statement on testing and reporting of anti-neutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol. 1999;111:507–13.PubMed Savige J, Gillis D, Benson E, et al. International consensus statement on testing and reporting of anti-neutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol. 1999;111:507–13.PubMed
5.
go back to reference Terjung B, Worman HJ, Herzog V, Sauerbruch T, Spengler U. Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy. Clin Exp Immunol. 2001;126:37–46.PubMedCrossRef Terjung B, Worman HJ, Herzog V, Sauerbruch T, Spengler U. Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy. Clin Exp Immunol. 2001;126:37–46.PubMedCrossRef
6.
go back to reference Silverberg MS, Satsangi J, Ahmed T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a working party of the 2005 Monteral World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5–36.PubMed Silverberg MS, Satsangi J, Ahmed T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a working party of the 2005 Monteral World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5–36.PubMed
7.
go back to reference Klebl FH, Bataille F, Bertea CR, et al. Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Sacchaomyces cerevisiae antibodies with Vienna classification subtypes of Crohn’s disease. Inflamm Bowel Dis. 2003;9:302–7.PubMedCrossRef Klebl FH, Bataille F, Bertea CR, et al. Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Sacchaomyces cerevisiae antibodies with Vienna classification subtypes of Crohn’s disease. Inflamm Bowel Dis. 2003;9:302–7.PubMedCrossRef
8.
go back to reference Frenzer A, Fierz W, Rundler E, Hammer B, Binek J. Atypical, cytoplasmic and perinuclear anti-neutrophil cytoplasmic antibodies in patients with inflammatory bowel disease. J Gastroenterol Hepatol. 1998;13:863–4.CrossRef Frenzer A, Fierz W, Rundler E, Hammer B, Binek J. Atypical, cytoplasmic and perinuclear anti-neutrophil cytoplasmic antibodies in patients with inflammatory bowel disease. J Gastroenterol Hepatol. 1998;13:863–4.CrossRef
9.
go back to reference Freeman H, Roeck B, Devine D, Carter C. Prospective evaluation of neutrophil autoantibodies in 500 consecutive patients with inflammatory bowel disease. Can J Gastroenterol. 1997;11:203–7.PubMed Freeman H, Roeck B, Devine D, Carter C. Prospective evaluation of neutrophil autoantibodies in 500 consecutive patients with inflammatory bowel disease. Can J Gastroenterol. 1997;11:203–7.PubMed
10.
go back to reference Sugi K, Saitoh O, Matsuse R, et al. Antineutrophil cytoplasmic antibodies in Japanese patients with inflammatory bowel disease: prevalence and recognition of putative antigens. Am J Gastroenterol. 1999;94:1304–12.PubMedCrossRef Sugi K, Saitoh O, Matsuse R, et al. Antineutrophil cytoplasmic antibodies in Japanese patients with inflammatory bowel disease: prevalence and recognition of putative antigens. Am J Gastroenterol. 1999;94:1304–12.PubMedCrossRef
11.
go back to reference Radice A, Vecchi M, Bianchi MB, Sinico RA. Contribution of immunofluorescence to the identification and characterization of anti-neutrophil cytoplasmic autoantibodies. The role of different fixatives. Clin Exp Rheumatol. 2000;18:707–12.PubMed Radice A, Vecchi M, Bianchi MB, Sinico RA. Contribution of immunofluorescence to the identification and characterization of anti-neutrophil cytoplasmic autoantibodies. The role of different fixatives. Clin Exp Rheumatol. 2000;18:707–12.PubMed
12.
go back to reference Perri F, Annese V, Piepoli A, et al. HLA antigens and pANCA define ulcerative colitis as a genetically heterogeneous disorder. Ital J Gastroenterol Hepatol. 1998;30:56–61.PubMed Perri F, Annese V, Piepoli A, et al. HLA antigens and pANCA define ulcerative colitis as a genetically heterogeneous disorder. Ital J Gastroenterol Hepatol. 1998;30:56–61.PubMed
Metadata
Title
Contribution of immunofluorescence to identification and characterization of antineutrophil cytoplasmic antibodies in inflammatory bowel disease
Authors
Dorra Bouzid
Samy Haddouk
Ali Amouri
Youssef Ben Hadj Hmida
Nabil Tahri
Hatem Masmoudi
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
Indian Journal of Gastroenterology / Issue 5/2011
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-011-0127-3

Other articles of this Issue 5/2011

Indian Journal of Gastroenterology 5/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.